Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells

Serk In Park1 and Laurie K McCauley1,2

1Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 North University Avenue, Ann Arbor, Michigan 48109, USA
2Department of Pathology, University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA

Abstract

Prostate cancer remains a leading cause of cancer-related death in men, largely attributable to distant metastases, most frequently to bones. Despite intensive investigations, molecular mechanisms underlying metastasis are not completely understood. Among prostate cancer-derived factors, parathyroid hormone-related peptide (PTHrP), first discovered as an etiologic factor for malignancy-induced hypercalcemia, regulates many cellular functions critical to tumor growth, angiogenesis, and metastasis. In this study, the role of PTHrP in tumor cell survival from detachment-induced apoptosis (i.e., anoikis) was investigated. Reduction of PTHLH (encoding PTHrP) gene expression in human prostate cancer cells (PC-3) increased the percentage of apoptotic cells when cultured in suspension. Conversely, overexpression of PTHrP protected prostate cancer cells (Ace-1 and LNCaP, both typically expressing low or undetectable basal PTHrP) from anoikis. Overexpression of nuclear localization signal (NLS)-defective PTHrP failed to protect cells from anoikis, suggesting that PTHrP-dependent protection from anoikis is an intracrine event. A PCR-based apoptosis-related gene array showed that detachment increased expression of the TNF gene (encoding the proapoptotic protein tumor necrosis factor-α) fourfold greater in PTHrP-knockdown PC-3 cells than in control PC-3 cells. In parallel, TNF gene expression was significantly reduced in PTHrP-overexpressing LNCaP cells, but not in NLS-defective PTHrP overexpressing LNCaP cells, when compared with control LNCaP cells. Subsequently, in a prostate cancer skeletal metastasis mouse model, PTHrP-knockdown PC-3 cells resulted in significantly fewer metastatic lesions compared to control PC-3 cells, suggesting that PTHrP mediated antianoikis events in the bloodstream. In conclusion, nuclear localization of PTHrP confers prostate cancer cell resistance to anoikis, potentially contributing to prostate cancer metastasis.

Introduction

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer-related death in males worldwide, notwithstanding the improved early detection methods and therapeutic modalities (Jemal et al. 2011). Advanced-stage prostate cancer patients commonly develop metastatic lesions, most frequently in the skeleton, which ultimately account for the high mortality rate as well as severe morbidities (Weilbaecher et al. 2011). In sharp contrast, the molecular mechanism leading to metastasis is not yet completely understood. Metastatic colonization in distant organs requires disseminating tumor cells to have essential cellular functions, such as invasion of extracellular matrices, survival in the bloodstream, extravasation, and
adaptation to the new environment (Langley & Fidler 2011), which are mediated by numerous tumor-derived factors. Prostate cancer is uniquely positioned because of its strong propensity to interact with and metastasize to bone. In this regard, prostate cancer cells express numerous bone-modulating cytokines including parathyroid hormone-related peptide (PTHrP), osteoprotegerin, receptor activator of nuclear factor-κB ligand, and others (Deftos et al. 2005). However, contributions of these bone-modulating factors to metastasis remain under investigation.

PTHRP was first discovered as an etiologic factor for malignancy-induced hypercalcemia by increasing osteoclastogenesis (Suva et al. 1987). Later, PTHrP expression was identified in carcinoma cells, such as lung, breast, and prostate cancer cells (Moseley et al. 1987, Iwamura et al. 1993, Downey et al. 1997). Similar to its physiologic counterpart, PTH, PTHrP binds to its cognate PTH/PTHrP receptor (PPR) expressed on osteoblasts and also found in some tumor cells (Downey et al. 1997, Iddon et al. 2000), triggering the cyclic AMP/protein kinase A signal transduction pathway. In addition to autocrine/paracrine effects mediated by receptor binding, PTHrP has been shown to localize to the nucleus, leading to the inhibition of apoptosis in chondrocytes and prostate cancer cells (Henderson et al. 1995, Dougherty et al. 1999). Chondrocytes expressing PTHrP with a deletion of the nuclear localization signal (NLS) showed increased apoptosis (Henderson et al. 1995), indicating that PTHrP functions as an antiapoptotic factor. However, the potential role of PTHrP in tumor cells, particularly in the context of metastatic cascades, is under investigation. For example, tumor cells are triggered to undergo apoptosis when the cells lose attachment to their extracellular matrix, a cellular phenomenon termed anoikis. Evasion of anoikis in the metastatic process (e.g. in the bloodstream) is essential for successful colonization of tumor cells in distant organs (Sakamoto & Kyriianou 2010).

In this study, the function of PTHrP in the context of prostate cancer was examined using an in vitro anoikis model as well as an in vivo experimental bone metastasis model. PTHrP protected prostate cancer cells from anoikis, effects of which were mediated by nuclear localization of PTHrP and reduced expression of tumor necrosis factor-α (TNF-α). Prostate tumor cells expressing lower PTHrP resulted in significantly fewer metastatic lesions compared to cells expressing higher PTHrP, potentially mediated by increased anoikis due to loss of intracrine PTHrP activity.

Materials and methods

Cells

PC-3, LNCaP, and Ace-1 prostate carcinoma cells were selected to study the function of PTHrP, because PC-3 cells express high levels of endogenous PTHrP while LNCaP and Ace-1 cells do not express detectable PTHrP. The canine prostate carcinoma cell line (Ace-1) was kindly provided by Dr Thomas Rosol (Ohio State University, USA; LeRoy et al. 2006, Thudi et al. 2011). Cells were maintained as monolayer cultures in RPMI-1640 media supplemented with 10% v/v fetal bovine serum and 1 × penicillin/streptomycin and glutamate (all from Invitrogen). For in vivo bioluminescence imaging, luciferase-labeled PC-3 cells (designated PC-3Luc) were produced by stably transfecting a luciferase-expressing pLazarus retroviral construct as previously described (Schneider et al. 2005). In addition, PTHLH (NCBI reference number: NM_198966) gene expression was reduced in PC-3Luc cells via a lentiviral vector (pLenti4/Block-iT DEST vector; Invitrogen) expressing short hairpin RNA targeting 5′-GGGCAGATACCTAACTCAGGA-3′. An empty vector was used as a control. Lentiviral supernatants were prepared using 293T packaging cells (the University of Michigan Viral Vector Core Laboratory, Ann Arbor, MI, USA), followed by transduction of PC-3Luc cells with polybrene (6 μg/ml). Subsequently, transduced cells were grown in bleomycin selection media (Zeocin 200 μg/ml; Invitrogen), and stable clones were selected and expanded for further experiments.

LNCaP and Ace-1 cells normally express undetectable basal levels of PTHrP. Both cell lines were stably transfected with full-length PTHrP, NLS-defective PTHrP (i.e. amino acids 87–107) (Henderson et al. 1995), or empty pcDNA3.1 vectors, as previously described (Dougherty et al. 1999, Liao et al. 2008).

Measurement of PTHrP

PTHRP expression was measured from the culture supernatant using an IRMA kit (Diagnostic Systems Laboratories, Webster, TX, USA), detecting amino acids 1–87 (Ratliffe et al. 1991). Briefly, one million cells were seeded in a six-well plate in complete RPMI-1640 media (in triplicate), followed by media change with serum-free RPMI-1640 24 h later. Subsequently, cells were incubated for 48 h and cell-free supernatants collected. The PTHrP assay was performed as suggested by the manufacturer.
Calculation of *in vitro* doubling time

PTHrP-knockdown and empty vector control PC-3Luc cells were synchronized (by overnight serum starvation), followed by seeding (1 × 10^5 cells/well, in triplicate) and enumeration at 24, 48, 72, and 96 h later with the aid of a hemacytometer and trypan blue dye. The doubling time \((T_d)\) was calculated using the formula: 

\[
T_d = \frac{(T_2 - T_1) \times \log(Q_2/Q_1)}{\log(2)}
\]

where \(Q_1\) and \(Q_2\) are cell numbers at two time points \((T_1\) and \(T_2\)) respectively.

In *vivo* tumor growth

All animal experimental protocols were approved and performed in accordance with current regulations and standards of the University of Michigan’s Institutional Animal Care and Use Committee guidelines.

For *in vivo* tumor growth, male athymic mice (Hsd: Athymic nude –Foxn1^nu; 4 weeks old; Harlan Laboratories, Indianapolis, IN, USA) were anesthetized and 100 µl of cell suspension containing 1 × 10^6 cells were mixed with 100 µl of growth factor reduced Matrigel (Invitrogen), and injected subcutaneously into both flanks \((n = 10\) each group). After 3 weeks, bioluminescence imaging was performed to measure tumor size, followed by euthanasia and tumor tissue harvesting.

Anoikis assay and flow cytometry

To induce anoikis *in vitro*, prostate cancer cells were cultured in suspension as previously described (Minard et al. 2006). Briefly, six-well tissue culture plates were covered with 4% w/v endotoxin-free agarose. Prostate cancer cells were ~80% confluent at the initiation of overnight serum-starvation (for synchronization). Subsequently, cells were trypsinized and counted, followed by seeding of 1 × 10^6 cells/well in RMPI-1640 media supplemented with 2% v/v fetal bovine serum on regular culture plates or agarose-covered plates (in sextuplicate). After 12–16 h of incubation at 37 °C, cells were harvested by pipetting (for cells in suspension) or trypsinization (for attached cells), followed by washing with ice-cold PBS and centrifugation.

For flow cytometric analyses, cells were re-suspended in Annexin V binding buffer (BD Biosciences, San Jose, CA, USA), followed by addition of FITC-conjugated anti-Annexin V and propidium iodide (BD Biosciences). Subsequently, cells were washed once with ice-cold PBS and analyzed by flow cytometer (BD FACSCalibur) with CellQuest analyses software (BD Biosciences).

![Figure 1](image-url) Generation of PC-3 prostate cancer cells expressing varying levels of PTHrP. PTHrP expression was reduced in PC-3Luc cells via lentiviral shRNA. (A) PTHrP protein levels were measured from the culture supernatant by IRMA. Data are average of two measurements ± S.D. Assays were repeated more than three times, and one set of representative data is shown. (B) *In vitro* doubling time of the PC-3 clones expressing varying levels of PTHrP was calculated by enumeration of viable cells at 24, 48, 72, and 96 h time points \((n = 3\) each). Data are mean ± S.D. NS, not significant. (C) *In vivo* tumor size was measured by bioluminescence imaging. Subcutaneous tumors were grown for 20 days \((n = 10\) per group). Five representative mice are shown. Tumor incidence was 100% in all three groups, determined by microscopic examination of tumor cells upon necropsy.
**Apoptotic gene array**

PTHrP-knockdown and empty vector control PC-3^{Luc} cells were grown on regular or 4% w/v agarose-covered 10 cm tissue culture plates (in duplicate) for 16 h. Subsequently, cells were lysed and total RNA was prepared (Qiagen RNeasy Mini Kit; Qiagen). RNA samples were reverse transcribed (RT^{2} First Strand Kit; SA Biosciences, Frederick, MD, USA), followed by quantitative PCR-based human apoptotic gene array (SA Biosciences) according to the manufacturer’s suggested protocols (Li et al. 2011). Analyses of data were performed using computer software provided by the manufacturer. A complete list of 84 apoptosis-related genes included in the analyses, detailed protocols, and analysis method can be found at the manufacturer’s website (http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-012A.html).

**In vivo metastasis model**

To test the metastatic potentials of PC-3^{Luc} clones, cells were inoculated into the systemic circulation via intracardiac route, as previously described (Park et al. 2011a), followed by *in vivo* bioluminescence imaging. In brief, male athymic mice (Hsd: Athymic nude – Foxn1nu; 6 weeks old; Harlan Laboratories) were anesthetized and 100 μl of cell suspension containing 2×10^{5} cells were injected into the left heart ventricle. Systemic circulation of the tumor cells was confirmed by *in vivo* bioluminescence imaging immediately after inoculation. Metastatic hind limb tumors were detected and quantified by bioluminescence imaging (Caliper Life Sciences, Alameda, CA, USA). Tumor-bearing hind limb bones were harvested at euthanasia, fixed in 10% v/v buffered formaldehyde and decalcified in 10% w/v EDTA for 2 weeks. Metastatic tumor cells were microscopically confirmed.

**Cytokines and antibodies**

Recombinant human TNF-α and anti-human TNF-α neutralizing antibodies were purchased from Peprotech, Inc. (Rocky Hill, NJ, USA). For western blotting, anti-PTHrP antibody (H-137: a rabbit polyclonal antibody against amino acids 41–177 of human PTHrP) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

**Statistical analyses**

All statistical tests were performed by Microsoft Excel or GraphPad Prism Version 5 (La Jolla, CA, USA).

---

**Figure 2** Reduction of PTHrP expression sensitized PC-3 cells to detachment-induced apoptosis. PC-3 cells expressing varying levels of PTHrP were induced to undergo anoikis, followed by flow cytometric analyses of apoptotic cells. Cells were seeded on regular six-well plates as a control, or on agarose-covered plates to induce anoikis (*n* = 6 each). (A, B, C, D and E) Representative flow cytometric dot plots are shown. Annexin V^+^PI^−^ cells (marked with boxes in the upper left quadrants) indicate apoptotic cells. (F) Average percentage of apoptotic cells is shown graphically. Data are mean ± s.d. *P* < 0.05 by Student’s *t*-test was considered statistically significant. NS, not significant.
USA). Student’s *t*-test was used to compare two groups and the $P<0.05$ level was considered statistically significant. All statistical tests were two-sided and data expressed as a mean ± S.D.

**Results**

**PTHRP-knockdown reduced *in vivo* tumor growth without affecting *in vitro* proliferation**

As a first approach to investigate the function of PTHrP in prostate cancer cells, *PTHLH* gene expression was reduced in PC-3Luc human prostate cancer cells using an shRNA technique. Stable clones were confirmed and selected according to level of PTHrP expression (Fig. 1A) in the cell culture supernatants. Two knockdown clones (clone no. 5 and 10) showed more than 50% reduction of PTHrP expression compared to parental PC-3Luc cells, while an empty vector control clone showed mild reduction, but not to the extent of clones 5 and 10. PTHrP has been shown to regulate cellular proliferation (Dougherty *et al*. 1999). However, cell enumeration assays demonstrated that PTHrP-knockdown did not affect *in vitro* cellular doubling time of PC-3Luc cells (Fig. 1B), suggesting that the reduced level of PTHrP expression was sufficient to maintain cellular proliferation, at least in PC-3Luc cells which express high basal levels of PTHrP. In contrast, PTHrP-knockdown resulted in significantly reduced tumor growth *in vivo* (Fig. 1C), suggesting that PTHrP regulates tumor cell proliferation and/or survival via a mechanism other than direct regulation of cell proliferation.

**Reduction of PTHrP expression sensitized PC-3Luc cells to detachment-induced apoptosis**

In routine maintenance subculturing, differential plating efficiency among PTHrP-knockdown and control clones was noted, leading to a hypothesis that PTHrP-knockdown PC-3 cells are more prone to detachment-induced apoptosis. To test this, PC-3Luc cells and PTHrP-knockdown clones were grown in suspension for an extended time, followed by flow cytometric analyses of apoptotic cells. Detachment increased the percentage of apoptotic Annexin V⁺PI⁻ cells (Fig. 2A and B), and empty vector control cells (Fig. 2C). Interestingly, PTHrP-knockdown clones had a significantly increased percentage of Annexin V⁺PI⁻ apoptotic cells (Fig. 2D, E and F),

![Figure 3 Ectopic expression of PTHrP rescued Ace-1 prostate cancer cells from anoikis. Ace-1 prostate cancer cells (expressing undetectable basal PTHrP) were engineered to express full-length PTHrP or control vector (pcDNA3.1), followed by anoikis assay. (A, B and C) Representative flow cytometric dot plots are shown. Annexin V⁺PI⁻ cells (marked with boxes in the upper left quadrants) indicate apoptotic cells. (D) Average percentage of apoptotic cells is shown graphically (n = 6). Data are mean ± S.D. $P<0.05$ by Student’s *t*-test was considered statistically significant.](https://www.endocrinology-journals.org)
indicating that reduction of PTHrP expression inhibits survival of prostate tumor cells in suspension.

**PTHrP overexpression rescued Ace-1 prostate cancer cells from anoikis**

To further investigate the role of PTHrP in anoikis, an alternative approach (i.e. ectopic expression of PTHrP) was employed. An additional prostate cancer cell line, Ace-1, had been previously shown to express undetectable levels of PTHrP (Liao et al. 2008). A PTHrP overexpression vector or empty pcDNA3.1 vector (as a control) was transfected into Ace-1 cells, resulting in Ace-1 PTHrP clone 10 and Ace-1 pcDNA respectively. PTHrP expression was measured and confirmed by IRMA of culture supernatants. The Ace-1 PTHrP clone 10 expressed 282.2 ± 9.83 (pg/ml per 1 × 10^6 cells per 48 h), while Ace-1 pcDNA control cells expressed undetectable levels of PTHrP. Cells were induced to undergo anoikis by culturing in suspension (Fig. 3). PTHrP overexpressing Ace-1 cells had significantly fewer apoptotic cells compared to Ace-1 pcDNA control cells (Fig. 3A, B, C and D), indicating a causal role of PTHrP in protection from anoikis.

**Recombinant PTHrP (1–34) failed to rescue PC-3 cells from anoikis**

Data in Figs 2 and 3 demonstrated that prostate tumor cells expressing higher PTHrP have increased survival from detachment-induced apoptosis. Because PTHrP functions primarily via paracrine/autocrine manners through its cognate PTH type 1 receptor (PPR), we next tested whether exogenous PTHrP would rescue the PTHrP-knockdown clones from anoikis. Recombinant PTHrP (amino acids 1 through 34, the functional PPR-binding fragment) or conditioned media from the parental PC-3Luc cell culture which contains full-length PTHrP was added to PTHrP-knockdown PC-3 clones in suspension. Neither recombinant PTHrP (1–34) nor the conditioned media rescued PTHrP-knockdown PC-3 cells from anoikis (Fig. 4), suggesting that PTHrP-dependent survival is not via N-terminus paracrine effects.

**Overexpression of full-length PTHrP, but not NLS-defective PTHrP, rescues prostate cancer cells from anoikis**

PTHrP localizes to the nucleus and has been shown to protect colon tumor cells from drug-induced apoptosis (Shen et al. 2007a, Bhatia et al. 2009b). This mechanism was evaluated on PTHrP- or NLS-defective PTHrP overexpressing prostate tumor cells. Human prostate cancer cells, LNCaP, expressing undetectable basal levels of PTHrP were engineered to express full-length PTHrP (designated PTHrP OE), NLS-defective PTHrP (designated PTHrP ΔNLS), or pcDNA3.1 (as a control) (Fig. 5G). Cells were cultured in suspension to induce anoikis, followed by flow cytometric analyses. Interestingly, NLS-defective PTHrP failed to rescue LNCaP...
cells from anoikis, while full-length PTHrP significantly supported LNCaP cell survival in suspension (Fig. 5A, B, C, D, E and F). Overall, Figs 1, 2, 3, 4 and 5 demonstrate that PTHrP promotes prostate tumor cell survival from detachment-induced apoptosis via an intracrine manner (nuclear localization) and not a paracrine manner, potentially contributing to tumor growth in vivo.

**Detachment induced greater TNF-α expression in PTHrP-knockdown PC-3 cells than in empty vector control cells**

To investigate downstream mediators of PTHrP-dependent anoikis, a quantitative PCR-based gene array (detecting 84 human apoptosis-related genes) experiment was performed. Detachment-induced genes were identified by comparing mRNA from cells cultured in an agarose-covered plate with cells cultured on a regular plate (columns (A) and (B) in Table 1). Among 84 apoptosis-related genes tested, tumor necrosis factor-α (TNF) gene expression was increased more than fourfold in PTHrP-knockdown PC-3 cells compared to empty vector control PC-3 cells, indicating an inverse correlation of PTHrP nuclear localization with a proapoptotic gene (TNF).

**NLS-defective PTHrP failed to decrease TNF in response to detachment**

To validate the observation in the gene array data (Table 1), detachment-induced TNF expression was confirmed in an additional cell line (LNCaP) expressing full-length PTHrP or NLS-defective PTHrP. Overexpression of PTHrP in LNCaP cells significantly reduced TNF gene expression, while NLS-defective PTHrP failed to do so, supporting a negative correlation between PTHLH expression and TNF (Fig. 6A). Data from Figs 1, 2, 3, 4, 5, 6 and Table 1 all together demonstrated that prostate tumor cells expressing higher PTHrP have increased resistance to anoikis by suppressing a proapoptotic gene (TNF).

**Recombinant TNF-α promotes anoikis and neutralizing TNF-α protects cells from anoikis**

The causal role of TNF-α in PTHrP-dependent anoikis was further examined. Recombinant human TNF-α administration promoted anoikis in empty vector control PC-3 cells (Fig. 6B). More importantly, neutralizing TNF-α reduced the percentage of apoptotic PTHrP-knockdown PC-3 cells in an in vitro anoikis experiment model (Fig. 6C). These results establish the
control PC-3 cells are shown in column (C).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Detachment-induced genes (fold)</th>
<th>(A) PTHrP-KD PC-3</th>
<th>(B) EV-control PC-3</th>
<th>(C) Fold changes ((A)/(B))</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF</td>
<td>4.829922</td>
<td>1.182631</td>
<td>4.08</td>
<td></td>
</tr>
<tr>
<td>CD40LG</td>
<td>1.571345</td>
<td>0.547906</td>
<td>2.87</td>
<td></td>
</tr>
<tr>
<td>BAK1</td>
<td>1.285206</td>
<td>0.693515</td>
<td>1.85</td>
<td></td>
</tr>
<tr>
<td>TNFSF8</td>
<td>1.134455</td>
<td>0.688725</td>
<td>1.65</td>
<td></td>
</tr>
<tr>
<td>GADD45A</td>
<td>1.387031</td>
<td>0.865737</td>
<td>1.60</td>
<td></td>
</tr>
<tr>
<td>BIRC8</td>
<td>2.891865</td>
<td>1.830198</td>
<td>1.58</td>
<td></td>
</tr>
<tr>
<td>PYCARD</td>
<td>0.612168</td>
<td>1.126619</td>
<td>0.54</td>
<td></td>
</tr>
<tr>
<td>HRK</td>
<td>1.118837</td>
<td>2.993846</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>CIDEA</td>
<td>0.53663</td>
<td>1.45599</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>TP73</td>
<td>0.185823</td>
<td>0.890076</td>
<td>0.21</td>
<td></td>
</tr>
</tbody>
</table>

PC-3Luc cells were transfected with PTHLH-targeting shRNA or empty lentiviral vectors, and stable clones were selected (designated PTHrP-KD and EV-control respectively). Cells were grown on a regular tissue-culture dish (control) and on agarose-covered plate to induce anoikis. Total RNA was prepared, followed by reverse transcription and quantitative PCR apoptotic gene array. Detachment-induced genes and fold induction in PTHrP-knockdown PC-3 cells are shown in column (A) (i.e. detachment effects in the PTHrP-knockdown clone = detached PTHrP-KD/attached PTHrP-KD), and those in empty vector control PC-3 cells (i.e. detachment effects in the control clone = detached EV-control/attached EV-control) are shown in column (B). To identify the anoikis genes altered by PTHrP reduction, fold changes comparing PTHrP-knockdown and control PC-3 cells are shown in column (C).

Table 1

causal relationship between TNF-α and PTHrP-mediated anoikis in PC-3 cells.

Reduction of PTHrP expression decreased prostate cancer skeletal metastasis

The biological significance of PTHrP-dependent resistance to anoikis was examined using an experimental prostate cancer skeletal metastasis model. Prostate cancer cells expressing high PTHrP were anticipated to produce more metastatic lesions via increased survival in the bloodstream, compared to prostate cancer cells expressing low PTHrP (Fig. 7). In our previous experiments, PC-3 cells develop metastatic lesions predominantly in bones (i.e. hind limbs and mandibles) in an intracardiac injection model (Schneider et al. 2005, Park et al. 2011a). Accordingly, PTHrP-knockdown or empty vector PC-3Luc cells were introduced into the systemic circulation and skeletal lesions were measured via in vivo bioluminescence imaging 5 weeks later. Because of differential in vivo growth rates (Fig. 1C), instead of comparing hind limb tumor size (quantified by photon emission from each lesion), incidence of hind limb metastatic lesions was reasoned to be a more appropriate comparison.

PTHrP-knockdown PC-3Luc (clone no. 10) produced significantly fewer hind limb metastatic lesions compared to empty vector control PC-3Luc cells, potentially due to decreased survival from anoikis in the bloodstream.

Discussion

The current study demonstrated that tumor-derived PTHrP promotes prostate cancer metastasis, in part, by conferring resistance to anoikis, and that the PTHrP-dependent protection from anoikis is mediated by nuclear translocalization. Reduction of PTHLH gene expression in PC-3 Luc human prostate cancer cells did not alter in vitro cellular proliferation but significantly decreased in vivo tumor growth, suggesting that PTHrP regulates cellular functions (evasion of apoptosis) in addition to previously known effects on proliferation. Indeed, PTHrP-knockdown cells had impaired ability to attach to the culture plates, leading to investigation of the mechanisms of PTHrP protection from anoikis. However, the discrepancy between in vitro proliferation and in vivo tumor growth might be attributable to other cellular functions. First, as wild-type PC-3 cells express high basal levels of PTHrP, reduction of PTHrP-expression to 20–40% (in PTHrP-knockdown clones 5 and 10) may not be sufficient to affect cellular proliferation, but enough to sensitize the cells to apoptotic stimuli. In addition, as PTHrP has been shown to regulate tumor angiogenesis (Liao et al. 2008), effects on in vivo tumor growth could simply be secondary to reduced angiogenesis. Murine endothelial cell-specific CD31/PECAM immunohistochemistry of the tumor tissue confirmed that PTHrP-knockdown tumors had significantly reduced mean vessel density (data not shown). Lastly, because PTHrP functions as a mediator in the crosstalk between the primary tumor and the bone/bone marrow, where a conducive environment is present, prostate tumors expressing low PTHrP may grow slower because of reduced recruitment of bone marrow-derived cells with tumorigenic functions (Park et al. 2011b). On the other hand, subsequent data (Figs 2, 3, 4 and 5) clearly demonstrated that PTHrP nuclear translocalization protects prostate tumor cells from anoikis, partly contributing to suppression of in vivo tumor growth of PTHrP-knockdown cells.

Antiapoptotic effects of PTHrP were first demonstrated in chondrocytes (Henderson et al. 1995), mediated by upregulation of the antiapoptotic protein BCL-2 (Amling et al. 1997). Later, PTHrP was shown to protect LoVo colon tumor cells from apoptosis by upregulating the PI3K/AKT pathway (Shen et al.
Additionally, PTHrP protected prostate tumor cells (C4-2 and PC-3) from chemotherapy-induced apoptosis in an intracrine manner (Bhatia et al. 2009a), of which observations were expanded by our current study. Therefore, PTHrP-mediated protection from apoptosis can be generalized to multiple inducers of apoptosis (e.g., chemotherapy, detachment, etc.), which can account for the correlation between PTHrP expression and metastatic potential of tumor cells (Hiraki et al. 2002, Liao & McCauley 2006). Apoptosis induced by disrupted epithelial cell–matrix interactions was described by Frisch & Francis (1994), and termed ‘anoikis.’ Evasion of anoikis was reasoned, and later proved to be a critical function of metastatic tumor cells (Yawata et al. 1998, Sakamoto et al. 2010). Data from the present study expand the role of PTHrP in protecting prostate tumor cells from anoikis, leading to decreased skeletal metastasis in PTHrP-knockdown cells compared to control PC-3 cells.

Interestingly, the PCR-based gene array data demonstrated that PTHrP prevents anoikis by down-regulating the proapoptotic gene TNF, which was confirmed in an additional human prostate cancer cell line. However, the mechanism of transcriptional downregulation by nuclear translocalization of PTHrP is unclear and requires further investigation. One potential mechanism underlying PTHrP-regulated gene expression is interaction with RNA. Aarts et al. (1999) demonstrated that nuclear PTHrP interacts with mRNA, which may lead to degradation of transcripts. Recently, deletion of mid-region, nuclear localization, and C-terminus of PTHrP (i.e. protein domains other than N-terminus which are recognized by the cognate receptor) decreased expression of genes essential for skeletal development (Runx1, Runx2, and Sox9) while increasing expression of cell cycle inhibitors (p21 and p16), supporting a role for PTHrP in transcriptional regulation (Toribio et al. 2010). Therefore, despite lack of definitive experimental evidence, nuclear localization of PTHrP may play critical roles in regulating gene expression, resulting in cellular phenotypes such as protection from apoptosis.

The current study has potential clinical significance by providing an additional molecular mechanism contributing to prostate cancer skeletal metastasis. Reduction of PTHrP resulted in decreased metastatic

**Figure 6** NLS-defective PTHrP failed to decrease TNF in response to detachment. (A) LNCaP cells were transfected with empty pcDNA3.1, PTHrP OE, or PTHrP ΔNLS vectors, and stable clones were selected. Cells were grown on regular tissue-culture dishes (control) and on agarose-covered plates to induce anoikis (n=3 each). Total RNA was prepared, followed by quantitative RT-PCR for TNF and GAPDH (for normalization). Normalized TNF gene expression from detached cells divided by normalized TNF expression from attached cells is shown graphically. Data are mean ± S.D. P<0.05 by Student’s t-test was considered statistically significant. (B) PC-3 empty vector control cells were seeded on agarose-covered plates to induce anoikis (n=5 each), followed by treatment with human recombinant TNF-α (0–200 ng/ml, as indicated). Apoptotic cells were quantified by flow cytometric analyses of Annexin V+ PI- cells. Data are mean ± S.D. P<0.05 by Student’s t-test was considered statistically significant. (C) PTHrP-knockdown (clone no. 10) or empty vector control PC-3 cells were seeded on agarose-covered six-well plates to induce anoikis (n=5 each). Anti-human TNF-α antibody (0.6 μg/ml) was added to neutralize TNF-α in the culture supernatant. Apoptotic cells were quantified by flow cytometric analyses of Annexin V+ PI- cells. Data are mean ± S.D. P<0.05 by Student’s t-test was considered statistically significant.
lesions in an experimental skeletal metastasis model. Incidence of skeletal metastatic lesions in hind limbs was significantly lower than the empty vector control group, not to mention hind limb metastatic tumor size (as determined by average photon emission from metastatic lesions in each group). However, we reasoned that the comparison of tumor size between two groups may not be an adequate approach to analyze the data, because two clones (empty vector control clone and PTHrP-knockdown clone) had significantly different growth potential in vivo, thus the hind limb tumor size quantification was not included in the data. Instead, as PTHrP-knockdown cells produced significantly fewer metastatic lesions in the hind limbs compared to 100% development of hind limb metastasis in the empty vector control cells, this likely reflects the altered ability for cells to survive the trajectory from injection to tumor cell lodging and growth in bone.

In conclusion, the current study demonstrates a role for PTHrP in protecting prostate tumor cells from anoikis in vitro, downregulating TNF gene expression, and supporting metastatic potential of prostate tumor cells in vivo.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was financially supported by the US Department of Defense Prostate Cancer Research Program Grants (grant numbers W81XWH-10-1-0546 (S I Park) and W81XWH-08-1-0037 (L K McCauley)); and the US National Cancer Institute Program Project Grant (grant number P01CA093900 (L K McCauley)).

Author contribution statement
L K McCauley supervised all experiments and manuscript preparation. S I Park and L K McCauley designed the experiments and analyzed the data. S I Park performed the experiments and wrote the manuscript.

Acknowledgements
The authors thank Janice E Berry, Amy J Koh, and Matthew Eber for their assistance in the preparation of this manuscript, and Thomas J Rosol for providing the Ace-1 prostate cancer cells.
References


Received in final form 24 January 2012
Accepted 30 January 2012
Made available online as an Accepted Preprint 30 January 2012